Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 10/20 | 0.40 |
| ▸ | CDK2 | P24941 | 10/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 10/20 | 0.40 |
| ▸ | DRD2 | P14416 | 6/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6787671 | 0.92 | CCNA2 (0.45) | CCNA2CDK2CCNA1DRD2ALDH1A1 | |
| SCHEMBL6793109 | 0.80 | STK17B (0.38) | DRD2SIGMAR1 | |
| SCHEMBL6791776 | 0.80 | CCNA2 (0.49) | CCNA2CDK2CCNA1 | |
| SCHEMBL6794639 | 0.79 | HCAR2 (0.42) | DRD2SIGMAR1 | |
| SCHEMBL6799794 | 0.79 | DRD2 (0.40) | CCNA2CDK2CCNA1DRD2SIGMAR1 | |
| SCHEMBL5233824 | 0.79 | CCNA2 (0.47) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL1658067 | 0.78 | CCNA2 (0.46) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6793699 | 0.78 | CCNA2 (0.46) | CCNA2CDK2CCNA1 | |
| SCHEMBL6792558 | 0.78 | CCNA2 (0.57) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6792168 | 0.78 | CCNA2 (0.46) | CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CCNA2 270/4885CDK2 29/4885CCNA1 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.